# Celldex Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2011

- Company: [Celldex Therapeutics, Inc.](/companies/cldx.md) (CIK 744218)
- Form: 10-Q
- Filed: 2011-08-04
- Accepted by EDGAR: Aug 4, 2011, 14:20 ET
- Period: 2011-06-30
- Accession: 0001104659-11-043630
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/744218/000110465911043630/a11-14029_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/744218/000110465911043630/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2011-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2011-04-01 to 2011-06-30 | $2.0m | us-gaap:Revenues |
| Revenue | 6 months, 2011-01-01 to 2011-06-30 | $4.5m | us-gaap:Revenues |
| Research and development | 3 months, 2011-04-01 to 2011-06-30 | $7.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2011-01-01 to 2011-06-30 | $14.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2011-04-01 to 2011-06-30 | −$9.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2011-01-01 to 2011-06-30 | −$19.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2011-04-01 to 2011-06-30 | $434.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2011-01-01 to 2011-06-30 | $920.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2011-04-01 to 2011-06-30 | −$10.2m | us-gaap:ProfitLoss |
| Net income | 6 months, 2011-01-01 to 2011-06-30 | −$20.3m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2011-04-01 to 2011-06-30 | −$0.27 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2011-01-01 to 2011-06-30 | −$0.58 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months, 2011-04-01 to 2011-06-30 | 37,463,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2011-01-01 to 2011-06-30 | 34,770,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2011-01-01 to 2011-06-30 | −$18.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2011-01-01 to 2011-06-30 | $282.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2011-06-30 | $10.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2011-06-30 | $73.3m | us-gaap:AssetsCurrent |
| Total assets | at 2011-06-30 | $118.5m | us-gaap:Assets |
| Current liabilities | at 2011-06-30 | $10.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2011-06-30 | $26.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2011-06-30 | $92.0m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/744218/000110465911043630/a11-14029_110q.htm

Filed Aug 4, 2011.
Source: SEC EDGAR, the filing index for accession 0001104659-11-043630. Last ingested by Listed: Nov 5, 2026, 19:04 ET. No prices; not investment advice.
